# Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma

> **NCT03137888** · PHASE2 · COMPLETED · sponsor: **Emory University** · enrollment: 30 (actual)

## Conditions studied

- Glioblastoma
- Gliosarcoma

## Interventions

- **RADIATION:** Dose-Escalated Radiation Therapy
- **PROCEDURE:** Spectroscopic Magnetic Resonance Imaging
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT03137888
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-20
- **Primary completion:** 2024-09-09
- **Final completion:** 2024-09-09
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2025-08-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03137888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03137888, "Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03137888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*